
OR WAIT null SECS
In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.
Hypersensitivity reactions, including anaphylaxis, can occur following administration of depemokimab, according to GSK’s December 2025 announcement of the agent’s FDA approval for severe eosinophilic asthma.¹ Across respiratory biologics, questions about when reactions occur, which patients face greater risk, and how long to observe patients in the office remain difficult to answer from spontaneous reporting data. A 2021 FAERS study of omalizumab, dupilumab, and allergen immunotherapy found most anaphylaxis symptoms occurred on the day of drug initiation, and omalizumab carried a positive reporting signal (reporting odds ratio, 2.24; 95% CI, 2.18 – 2.29).²
A retrospective FAERS analysis presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix compared anaphylaxis reporting proportions across 7 respiratory biologics using reports from October 2020 through March 2026.³ Omalizumab had the highest proportion (5.95% overall; 4.45% with respiratory indications), and dupilumab had the lowest among established agents (0.15% overall; 0.31% with respiratory indications).³ Restricting the analysis to respiratory indications shifted proportions in different directions by agent, and dashboard data could not support assessment of time to onset, dose number, age, sex, or concomitant allergen immunotherapy.³
Jennifer K. Priessnitz, MD, a resident at Macon & Joan Brock Virginia Health Sciences at Old Dominion University, presented the oral abstract and cautions against changing biologic selection based on reporting proportions alone. She encourages clinicians to document reaction timing, dose number, and outcomes when reporting suspected cases. Below, Priessnitz shares her perspective on in-office observation, patient-level risk factors, and the registry and pharmacovigilance work needed to estimate true anaphylaxis incidence.
HCPLive: What did the data show about the timing of onset, and what does it mean for in-office observation periods?
Jennifer K. Priessnitz, MD: Time to onset and the relationship between anaphylaxis and the number of doses administered are important considerations when evaluating biologic safety. However, these variables could not be reliably assessed in our analysis.
Our study utilized publicly available FAERS dashboard case-level line listings, which provided information on reported adverse events, treatment indications, and clinical outcomes but did not contain sufficiently detailed and consistent treatment-timing information to determine whether anaphylaxis occurred following an initial dose or later in therapy.
The more comprehensive quarterly FAERS datasets contain additional information that may support evaluation of treatment and reaction timing. However, these analyses require linking multiple datasets, and incomplete or inconsistent dates can limit the reliability of calculated onset intervals.
Consequently, our findings cannot establish when patients are most likely to experience anaphylaxis or support modifications to existing in-office observation periods.
From a clinical perspective, monitoring should continue to follow the prescribing information and established recommendations for each biologic. Importantly, prior tolerance does not necessarily eliminate the possibility of a subsequent hypersensitivity reaction, and clinicians should remain prepared to recognize and manage anaphylaxis whenever these medications are administered.
HCPLive: Did any patient or treatment factors stand out, such as age, sex, indication, or concomitant allergen immunotherapy?
Jennifer K. Priessnitz, MD: The primary clinical characteristic we evaluated was treatment indication, specifically whether reports contained a qualifying respiratory indication such as asthma, chronic rhinosinusitis with nasal polyps, COPD, or eosinophilic granulomatosis with polyangiitis.
We found that anaphylaxis reporting proportions differed between the overall reporting population and the respiratory subgroup, although the direction of these differences varied by biologic. For example, dupilumab demonstrated a higher reporting proportion in the respiratory subgroup, whereas omalizumab demonstrated a lower proportion.
This was an important finding because several biologics are approved for multiple allergic and inflammatory conditions, and the characteristics of patients receiving these therapies may differ substantially.
However, our analysis was not designed to identify individual patient-level predictors of anaphylaxis. We were unable to reliably evaluate age, sex, baseline asthma severity, concomitant allergen immunotherapy, or other potentially relevant clinical characteristics using the available dashboard data.
These factors warrant further investigation. Poorly controlled asthma is associated with increased severity of anaphylactic reactions in certain clinical settings, but our findings cannot establish whether asthma control or underlying respiratory disease severity influenced the observed biologic-associated reporting patterns.
HCPLive: Should these results change how clinicians choose biologics or monitor patients with prior anaphylaxis or multiple allergic comorbidities?
Jennifer K. Priessnitz, MD: I would not recommend changing biologic selection based on these findings alone. Although we observed differences in anaphylaxis reporting proportions across agents, FAERS is a spontaneous reporting system and cannot establish causality, determine the true incidence of anaphylaxis, or provide a direct comparison of patient-level risk.
Biologic selection should continue to be individualized based on the patient’s underlying disease, inflammatory phenotype, comorbidities, anticipated treatment benefit, and the established safety profile of each medication.
For patients with a history of anaphylaxis or multiple allergic comorbidities, our findings reinforce the importance of obtaining a detailed reaction history, discussing potential hypersensitivity reactions, and following medication-specific administration and monitoring recommendations.
It is also important to distinguish a history of anaphylaxis from a confirmed hypersensitivity reaction to the biologic itself, since these have different implications for treatment selection and potential contraindications.
I view these findings as supporting informed clinical decision-making and continued pharmacovigilance rather than suggesting that clinicians should preferentially prescribe one biologic over another based on reporting proportions alone. These therapies provide substantial benefits for patients with difficult-to-control respiratory disease, and safety considerations must be balanced against their established efficacy.
HCPLive: What questions remain open, and what would you like to see from future research and clinicians in practice?
Jennifer K. Priessnitz, MD: Several important questions remain unanswered, particularly regarding which patients may be more susceptible to biologic-associated anaphylaxis and whether specific clinical characteristics influence the timing or severity of these reactions.
One priority for future research is integrating the more detailed quarterly FAERS datasets to evaluate demographic characteristics, time to onset, number of doses administered before a reaction, and concomitant medications. These analyses could help characterize reported events more comprehensively and identify potential patterns that were not accessible through our current approach.
Additional pharmacovigilance analyses using reporting odds ratios or proportional reporting ratios may help further evaluate disproportionate reporting of anaphylaxis across agents. However, these methods would still be limited by the inherent biases of spontaneous reporting systems.
Prospective registries and large observational studies with reliable medication-exposure denominators are needed to better estimate actual anaphylaxis incidence and identify potential patient-level risk factors.
From a clinical standpoint, I would encourage continued reporting of suspected biologic-associated anaphylaxis, with particular attention to documenting reaction timing, dose number, clinical manifestations, concomitant medications, treatment administered, and patient outcomes. More complete reporting can strengthen postmarketing surveillance and ultimately improve our understanding of these rare but potentially serious adverse events.
References
Related Content: